Charles River Laboratories International (CRL)
(Real Time Quote from BATS)
$204.18 USD
+5.63 (2.84%)
Updated Aug 15, 2024 12:02 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 277 | 234 | 241 | 228 | 238 |
Receivables | 780 | 752 | 643 | 618 | 514 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 380 | 256 | 199 | 186 | 161 |
Other Current Assets | 171 | 197 | 191 | 169 | 109 |
Total Current Assets | 1,609 | 1,439 | 1,274 | 1,201 | 1,021 |
Net Property & Equipment | 1,640 | 1,466 | 1,291 | 1,124 | 1,044 |
Investments & Advances | 244 | 312 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 40 | 41 | 40 | 38 | 45 |
Intangibles | 3,959 | 3,805 | 2,792 | 1,875 | 1,616 |
Deposits & Other Assets | 309 | 148 | 1,334 | 1,074 | 826 |
Total Assets | 8,195 | 7,603 | 7,024 | 5,491 | 4,693 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 169 | 206 | 198 | 122 | 112 |
Current Portion Long-Term Debt | 0 | 0 | 3 | 50 | 39 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 441 | 417 | 475 | 357 | 298 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 445 | 469 | 357 | 310 | 262 |
Total Current Liabilities | 1,055 | 1,092 | 1,033 | 840 | 710 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 191 | 216 | 240 | 217 | 167 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,647 | 2,708 | 2,664 | 1,930 | 1,850 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 223 | 175 | 243 | 205 | 183 |
Minority Interest (Liabilities) | 57 | 42 | 53 | 26 | 29 |
Total Liabilities | 4,593 | 4,622 | 4,485 | 3,373 | 3,055 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 1,906 | 1,805 | 1,718 | 1,628 | 1,532 |
Retained Earnings | 1,887 | 1,433 | 981 | 625 | 280 |
Other Equity | -191 | -257 | -161 | -135 | -175 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3,602 | 2,981 | 2,539 | 2,118 | 1,638 |
Total Liabilities & Shareholder's Equity | 8,195 | 7,603 | 7,024 | 5,491 | 4,693 |
Total Common Equity | 3,602 | 2,981 | 2,539 | 2,118 | 1,638 |
Shares Outstanding | 51.30 | 50.90 | 50.40 | 49.70 | 48.90 |
Book Value Per Share | 70.22 | 58.57 | 50.38 | 42.62 | 33.49 |
Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 179 | 327 | 277 | 157 | 200 |
Receivables | 762 | 787 | 780 | 799 | 801 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 349 | 361 | 380 | 293 | 285 |
Other Current Assets | 209 | 193 | 171 | 195 | 218 |
Total Current Assets | 1,499 | 1,668 | 1,609 | 1,444 | 1,505 |
Net Property & Equipment | 1,614 | 1,619 | 1,640 | 1,525 | 1,530 |
Investments & Advances | 232 | 244 | 244 | 302 | 300 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 36 | 37 | 40 | 34 | 39 |
Intangibles | 3,880 | 3,898 | 3,959 | 3,771 | 3,846 |
Deposits & Other Assets | 301 | 303 | 309 | 155 | 155 |
Total Assets | 7,948 | 8,153 | 8,195 | 7,607 | 7,772 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 133 | 130 | 169 | 136 | 140 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 369 | 381 | 441 | 422 | 412 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 446 | 445 | 445 | 435 | 456 |
Total Current Liabilities | 948 | 955 | 1,055 | 994 | 1,008 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 165 | 180 | 191 | 185 | 207 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,409 | 2,660 | 2,647 | 2,514 | 2,678 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 225 | 223 | 173 | 177 | |
Minority Interest (Liabilities) | 46 | 58 | 57 | 40 | 42 |
Total Liabilities | 4,221 | 4,507 | 4,593 | 4,296 | 4,515 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,957 | 1,939 | 1,906 | 1,877 | 1,850 |
Retained Earnings | 2,054 | 1,960 | 1,887 | 1,720 | 1,633 |
Other Equity | -265 | -244 | -191 | -263 | -202 |
Treasury Stock | 18 | 9 | 0 | 24 | 24 |
Total Shareholder's Equity | 3,727 | 3,646 | 3,602 | 3,311 | 3,258 |
Total Liabilities & Shareholder's Equity | 7,948 | 8,153 | 8,195 | 7,607 | 7,772 |
Total Common Equity | 3,727 | 3,646 | 3,602 | 3,311 | 3,258 |
Shares Outstanding | 51.60 | 51.50 | 51.30 | 51.30 | 51.20 |
Book Value Per Share | 72.23 | 70.80 | 70.22 | 64.54 | 63.62 |